Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / RESEARCH LETTER
The prognostic value of cancer stem cell markers in thyroid cancer: a systematic review
1
Department of Oncology, Army Medical Center of PLA, Chongqing, China
2
College of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China
These authors had equal contribution to this work
Submission date: 2024-01-09
Acceptance date: 2024-02-22
Online publication date: 2024-03-11
Corresponding author
Arch Med Sci 2024;20(2):686-690
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Thyroid cancer stem cells (TCSCs) play a crucial role in the pathogenesis, metastasis, and therapeutic response of thyroid cancer, making them promising biomarkers and potential targets for clinical intervention. This systematic review aims to qualitatively assess the impact of commonly used TCSC markers on the prognosis of thyroid cancer using qualitative methods.
Material and methods:
In total, the analysis encompassed five articles.
Results:
Six TCSC markers were involved, among which CD133, CD44, CD24, CD15 and ALDH1 were associated with the prognosis of thyroid cancer.
Conclusions:
However, the utility of these TCSC markers in clinical practice for predicting the prognosis of thyroid cancer requires further research to provide additional evidence supporting their effectiveness.
Thyroid cancer stem cells (TCSCs) play a crucial role in the pathogenesis, metastasis, and therapeutic response of thyroid cancer, making them promising biomarkers and potential targets for clinical intervention. This systematic review aims to qualitatively assess the impact of commonly used TCSC markers on the prognosis of thyroid cancer using qualitative methods.
Material and methods:
In total, the analysis encompassed five articles.
Results:
Six TCSC markers were involved, among which CD133, CD44, CD24, CD15 and ALDH1 were associated with the prognosis of thyroid cancer.
Conclusions:
However, the utility of these TCSC markers in clinical practice for predicting the prognosis of thyroid cancer requires further research to provide additional evidence supporting their effectiveness.
REFERENCES (20)
1.
Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013; 2013: 965212.
2.
Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016; 12: 646-53.
3.
Edafe O, Wadsley J, Harrison BJ, Balasubramanian SP. Treatment related morbidity in differentiated thyroid cancer-a survey of clinicians. Thyroid Res 2014; 7: 3.
4.
Wang J, Xiang C, Cai Y, et al. Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis. Arq Neuropsiquiatr 2022; 80: 1254-61.
5.
Lu L, Wu M, Sun L, et al. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: a comprehensive meta-analysis with 4729 patients involved. Medicine (Baltimore) 2016; 95: e5163.
6.
Al-Mosawi AKM, Cheshomi H, Hosseinzadeh A, Matin MM. Prognostic and clinical value of CD44 and CD133 in esophageal cancer: a systematic review and meta-analysis. Iran J Allergy Asthma Immunol 2020; 19: 105-16.
7.
Shakib H, Rajabi S, Dehghan MH, Mashayekhi FJ, Safari-Alighiarloo N, Hedayati M. Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review. Endocrine 2019; 66: 435-55.
8.
Oh EJ, Bychkov A, Cho H, et al. Prognostic implications of CD10 and CD15 expression in papillary thyroid carcinoma. Cancers 2020; 12: 1413.
9.
Bi Y, Meng Y, Wu H, Cui Q, Luo Y, Xue X. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: a ten-year follow-up and prognostic analysis. J Surg Oncol 2016; 113: 144-51.
10.
Kim HM, Koo JS. Immunohistochemical analysis of cancer stem cell marker expression in papillary thyroid cancer. Front Endocrinol 2019; 10: 523.
11.
Ryu YJ, Choe JY, Lee K, Ahn SH. Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma. Oncol Letters 2020; 19: 343-9.
12.
Cordero-Barreal A, Caleiras E, López de Maturana E, et al. CD133 expression in medullary thyroid cancer cells identifies patients with poor prognosis. J Clin Endocrinol Metabol 2020; 105: dgaa527.
13.
Friedman S, Lu M, Schultz A, Thomas D, Lin RY. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One 2009; 4: e5395.
14.
Wang C, Wang Z, Liu W, Ai Z. CD133 promotes the self-renewal capacity of thyroid cancer stem cells through activation of glutamate aspartate transporter SLC1A3 expression. Biochem Biophys Res Commun 2019; 511: 87-91.
15.
Biermann K, Biersack HJ, Sabet A, Janzen V. Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma. Semin Nuclear Med 2011; 41: 139-48.
16.
Ke CC, Liu RS, Yang AH, et al. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nuclear Med Mol Imaging 2013; 40: 61-71.
17.
Ahn SH, Henderson YC, Williams MD, Lai SY, Clayman GL. Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metabol 2014; 99: 536-44.
18.
Guo JJ, Xu HS, Wu G, Ma ZY. p63 inhibits CD44(+)/CD24(-) cell proliferation and chemoresistance in papillary thyroid carcinoma cells. Exp Ther Med 2017; 14: 4693-6.
19.
Xing Y, Luo DY, Long MY, Zeng SL, Li HH. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma. World J Surg Oncol 2014; 12: 29.
20.
Cui Y, Liu Y, Mu L, Li Y, Wu G. Transcriptional expressions of ALDH1A1/B1 as independent indicators for the survival of thyroid cancer patients. Front Oncol 2022; 12: 821958.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
